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Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Department, Lausanne, SwitzerlandThe detection of driver mutations in the epidermal growth
factor receptor (EGFR), the rearrangement of anaplastic lym-
phoma kinase (ALK) genes and the subsequent development
of targeted therapy have transformed the treatment of lung
cancer. In a Caucasian population, as illustrated by the Bio-
marker France database, these alterations represent 9.4%
and 4.0%, respectively, in 10,000 samples of non-small-cell
lung cancer (NSCLC) [1]. Of these patients, 56.9% received
treatment according to their molecular profile, either with la-
belled drugs or in a bio-guided trial. Similarly, the Lung Can-
cer Mutation Consortium, after testing more than 1000
patients with lung adenocarcinoma, found 15% to harbour
an EGFR mutation and 8% an ALK rearrangement [2]. An
actionable driver alteration was detected in 62% of these tu-
mours. The use of targeted therapies has raised practical
questions related to therapy sequences and durations, the
role of chemotherapy, the role of combination with chemo-
therapy, the validity of Response Evaluation Criteria in Solid
Tumours (RECIST) criteria, utility of therapeutic rechallenge
with the same drugs and several additional issues that arise
in the wake of all significant medical progress. This article
will address some of these questions and highlight some
areas of controversy.
2. Whom and when to test?
The College of American Pathologists recommends testing for
EGFR mutations and ALK rearrangements in all patients with
lung adenocarcinoma, irrespective of clinical characteristics.
In the setting of lung cancer resection specimen availability,
EGFR and ALK testing is recommended for adenocarcinomas
andmixed lung cancers with an adenocarcinoma component,
but is not recommended in lung cancer that lacks any adeno-
carcinoma component. In the setting of more limited lung
cancer specimens (biopsy, cytology) where an adenocarci-
noma component cannot be excluded, EGFR and ALK testing
may be performed in cases showing squamous- or small-cellhistology, with clinical criteria such as young age and lack of
smoking history being useful in selecting the subset for test-
ing. Primary tumours or metastatic lesions are considered
equally suitable for testing, and testing of many different
areas within a single tumour is not necessary. For patients
with multiple, apparently separate, primary lung adenocarci-
nomas, each tumour should be evaluated. Testing should be
ordered at the time of initial diagnosis of advanced-stage dis-
ease (stage IV according to the tumour-node-metastasis
(TNM) staging system 7th edition) or at the time of recurrence
or progression in patients who originally presented with low-
er-stage disease. Testing for EGFR should be prioritised over
other molecular markers, followed by ALK, and only later
other molecular markers in lung adenocarcinoma, for which
published evidence is insufficient to support the development
of testing guidelines at the present time [3].
3. When to start treatment?
First-line EGFR tyrosine kinase (TKI) therapy in patients
whose tumour harbours an activating mutation of the EGFR
gene has not translated into prolonged overall survival in four
randomised trials with mature overall survival (OS) data [4–7],
owing to the fact that the vast majority of patients receiving
chemotherapy as first-line treatment received EGFR TKI as
salvage therapy upon disease progression [4–9].
Why do guidelines advocate use of first-line over chemo-
therapy [10]? To start with, EGFR mutational status may be al-
tered under first-line chemotherapy, and selection of patients
for targeted therapy on the basis of molecular testing on the
initial biopsy may be inadequate [11]. Furthermore, in the
randomised trials, up to 41% of patients treated with initial
chemotherapy did not receive second-line EGFR TKI, mostly
because of rapid tumour progression leading to death or re-
duced performance status, thus excluding these patients
form the opportunity to receive the most efficient treatment
[5–7]. Quality-of-life data also favour use of EGFR TKI over
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cranial response rate of EGFR TKIs may defer use of cerebral
radiotherapy in patients with central nervous system meta-
static disease.
ALK TKIs such as crizotinib are being studied for first-line
treatment. Their use is restricted to second and further lines
at the present time. OS has not been reported, and is unlikely
to be improved as the study design allowed for cross-over to
crizotinib in the control arms upon disease progression.
4. Which TKI to choose?
Gefitinib, erlotinib and afatinib have shown significant pro-
longation of progression-free survival (PFS) in the first-line
setting as compared with a platinum doublet. No adequately
powered trial has compared these TKIs. Gefitinib and erlotinib
are both appropriate as first-line treatment, afatinib being
commercially unavailable at the present time with a possible
slightly higher gastrointestinal toxicity.
5. When to stop treatment?
All patients on EGFR TKI ultimately develop acquired resis-
tance, which translates into progressive disease as per RECIST
criteria. However, only a fraction of tumour clones might car-
ry a resistance mechanism, and interruption of TKI therapy
may result in tumour flares. The ASPIRATION trial
(NCT01310036) currently compares PFS evaluated by RECIST
criteria with PFS until ‘progressive disease according to the
investigator’, defined as symptomatic progression, multiple
progression or threat to a major organ. A randomised phase
II trial compared chemotherapy plus erlotinib with chemo-
therapy alone in EGFR TKI-responsive NSCLC that subse-
quently progresses [12]. No improvement in PFS or OS could
be detected, although the number of enrolled patients was
low and the trial terminated early. Improvement in RR but
not in PFS or OS could be shown in a recent retrospective trial
[13]. However, the controversy about continuing EGFR TKI be-
yond progression is ongoing, with promising retrospective re-
sults reported against the switch to chemotherapy [14,15] or
by adding local treatment to TKI [16], or combining TKI with
chemotherapy [17]. The IMPRESS trial is an ongoing phase
III trial expected to clarify the role of TKIs beyond progression.
For progression limited to the brain, local therapy to the area
of progression may lead to prolonged disease control.
6. What to do upon disease progression?
Despite initial activity of EGFR TKIs, all patients eventually de-
velop acquired resistance. The most common mechanism of
resistance is the EGFR T790M secondary mutation, which ac-
counts for 50–60% of cases, and results in increased kinase
affinity for adenosine triphosphate [18]. Second-generation
EGFR TKIs – such as neratinib, afatinib and dacomitinib –
are effective in preclinical gefitinib- and erlotinib-resistant
EGFR T790M models, but to date their delivery in EGFR TKI-
resistant patients have shown disappointing results in the
clinic. Combination of afatinib with cetuximab in EGFR TKI-
resistant patients resulted in a 30% response rate and 75%disease control rate, with significant gastrointestinal toxicity
[19]. Other mechanisms of resistance include MET amplifica-
tion, with no commercially available inhibitor, HER2 amplifi-
cation potentially amenable to treatment with anti-HER2
monoclonal antibodies or histological transformation to
small-cell lung cancer, which requires cytotoxic chemother-
apy. Additional potential mechanisms of acquired resistance
to EGFR TKIs may develop, including altered EGFR trafficking,
amplification or activation of downstream or overlapping
pathways and expression of drug-efflux transporters. Stan-
dard treatment upon progression on EGFR TKI remains cyto-
toxic chemotherapy. Later rechallenge with EGFR TKI may
result in some modest degree of response (range 4–24%) and
a significant disease control rate (range 45–67%) [20–22].
Resistance mechanisms to crizotinib are multiple, and in-
clude ALK-dominant mechanisms such as resistance muta-
tions and copy number gain, and ALK non-dominant
mechanisms through the outgrowth of clones containing a
separate activated oncogene. In contrast to the EGFR setting,
where the T790M mutation predominates, the spectrum of
ALK resistance mutations is broad. Several distinct second-
generation ALK inhibitors which are potentially efficient in
preventing/overcoming TKI resistance are under develop-
ment. A response rate of 80% has been observed during treat-
ment with LDK378 in patients who had experienced disease
progression after crizotinib treatment [23]. Similarly to EGFR
TKIs, successful later rechallenge with ALK inhibitors has
been reported in case reports [24].
7. What toxicity to expect?
Grade 3 or 4 toxicities occur infrequently with EGFR TKIs, with
the exception of skin rash, fatigue and diarrhoea (13%, 6% and
5%, respectively in the Caucasian European Randomised Trial
of Tarceva versus Chemotherapy (EURTAC) cohort). Grade 1 or
2 toxicities, however, occur in most patients, with rash, fati-
gue and diarrhoea bothering the majority of patients (67%,
51% and 52%, respectively), and with appetite loss, alopecia,
anaemia and arthralgia occurring in a minority of patients
(31%, 14%, 11% and 10%, respectively). Rare but potentially
fatal interstitial pneumonitis occurs in 1% of patients. Overall,
one third of patients require dose reduction or treatment dis-
continuation because of adverse effects [9]. Topical skin care
is mandatory. Systemic antibiotics and anti-diarrhoeal drugs
may be necessary to manage higher-grade toxicity.
Frequent toxicities of the ALK inhibitor crizotinib include
vision disorders (62%), nausea (53%) and diarrhoea (43%). Pa-
tients are less frequently affected by oedema (28%), constipa-
tion (27%), fatigue (20%) decreased appetite (19%), dizziness
(16%) and dysgeusia (12%). Potentially dose-limiting, in-
creased alanine aminotransferase levels occur in 13% of pa-
tients, with less than 5% being of grade 3 or 4. Rapid-onset
low testosterone is common in male patients. Renal cysts
and pneumonitis have been described, but their frequency
is unknown [25,26].
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